Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **vero cell-derived trivalent influenza vaccine (modified)** is an inactivated influenza vaccine produced using the Vero cell line (derived from African green monkey kidney cells), instead of the traditional embryonated chicken eggs[1][2][3][6][8]. This vaccine contains inactivated viral antigens from three influenza strains: typically two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage (B/Victoria), as recommended for recent influenza seasons[5][7][9]. Vero cell-based production offers advantages including scalability, faster production, and suitability for those with egg allergies[2][3][6][8]. The “modified” formulation refers to changes in composition or production, such as strain selection or cell culture optimization[5][7]. The vaccine works by stimulating the immune system to produce antibodies against the included strains, thereby providing prophylactic protection against influenza infection[3]. Clinically, Vero cell-derived trivalent influenza vaccines have demonstrated efficacy (~78.5% for matched strains) and a favorable safety profile[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vero cell-derived trivalent influenza vaccine (modified).